Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Tuberculosis (Edinb). 2014 Apr 1;94(3):271–276. doi: 10.1016/j.tube.2014.03.007

Figure 4.

Figure 4

Efficacy in acute animal models of tuberculosis. (A) Scatter plots of the bacterial CFU counts from lungs (●) and spleen (▲) from untreated control animals and the lungs (■) and spleen (▼) of infected mice after treatment with SB-P3G2 delivered IP at 150 mg/kg for 9 consecutive days to immune incompetent GKO mice. SB-P3G2 reduced the bacterial load of M. tuberculosis H37Rv 0.71 ± 0.17 log10 CFU in the lungs and 0.41 ± 0.36 log10 CFU in spleen. (B) Scatter plots of the bacterial CFU counts from spleen (▲) from untreated control animals and the spleen (▼) of infected mice after treatment with SB-P3G2 delivered IP at 100 mg/kg BID for 10 consecutive days to immune competent C57BL/6 mice. SB-P3G2 reduced the bacterial load of M. tuberculosis Erdman in the spleen log10 1.6 ± 0.49. In both studies, no outliers were identified by the Grubbs’ Test.